The first project is to develop comprehensive panels to profile infectious diseases. Seegene’s proprietary technologies for multiplexed real-time PCR analysis enable simultaneous amplification of up to 20 target genes per tube in a single reaction.

QIAGEN will validate the new tests to run on QIAsymphony RGQ MDx, its flagship automation solution, and will market them worldwide as QIAGEN-branded assays, beginning in Europe and Asia.

"We are excited to bring to our customers valuable new tests for QIAsymphony RGQ MDx by partnering with Seegene to develop and commercialize novel multiplex assays. Seegene’s technologies can test for multiple targets with high sensitivity, reproducibility, and the panels offer significant medical value," said Thierry Bernard Senior Vice President, Head of the Molecular Diagnostics Business Area and a member of the Executive Committee of QIAGEN.

Dr. Jong-Yoon Chun, Founder and CEO of Seegene, said: "Collaborating with QIAGEN to commercialize comprehensive multiplexed panels based on our innovative PCR chemistry technologies will expand Seegene’s global reach."

QIAsymphony is an innovative, easy-to-use modular system that integrates a molecular laboratory’s workflow from initial biological sample processing to final insights.

The three modules of QIAsymphony RGQ MDx are QIAsymphony SP for sample preparation, QIAsymphony AS for assay setup (integrated into the SP module), and QIAGEN’s real-time PCR detection platform Rotor-Gene Q MDx. QIAsymphony RGQ MDx received FDA clearance in early 2014.

The menu of diagnostics running on the QIAsymphony platform so far includes 13 CE-IVD marked tests available in 30 European countries and six FDA-approved or cleared diagnostics in the US.

QIAGEN’s first highly multiplexed assay running on Rotor-Gene Q, the RespiFinder RG Panel for detection and differentiation of 21 respiratory pathogens, was recently launched in Europe.